ASSESSING THE PUBLIC HEALTH IMPACT OF THE ADJUVANTED RESPIRATORY SYNCYTIAL VIRUS PREFUSION F PROTEIN VACCINE AMONG OLDER ADULTS IN THE UNITED STATES (US)

被引：0
|
作者：
Molnar, D. [1 ]
La, E. M. [2 ]
Verelst, F. [1 ]
Curran, D. [1 ]
Poston, S. [2 ]
Van Bellinghen, L. A. [3 ]
Graham, J.
机构：
[1] GSK, Wavre, WBR, Belgium
[2] GSK, Philadelphia, PA USA
[3] CHESS Hlth, Bonheiden, Belgium
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EPH45
引用
收藏
页码：S172 / S172
页数：1
相关论文
共 50 条
  • [21] The potential public health impact of the respiratory syncytial virus prefusion F protein vaccine in people aged ≥60 years in Japan: results of a Markov model analysis
    Kurai, Daisuke
    Mizukami, Akiko
    Preckler, Victor
    Verelst, Frederik
    Molnar, Daniel
    Matsuki, Taizo
    Ho, Yufan
    Igarashi, Ataru
    EXPERT REVIEW OF VACCINES, 2024, 23 (01) : 303 - 311
  • [22] Immunogenicity of an AS01-adjuvanted respiratory syncytial virus prefusion F (RSVPreF3) vaccine in animal models
    Bouzya, Badiaa
    Rouxel, Ronan Nicolas
    Sacconnay, Lionel
    Mascolo, Romuald
    Nols, Laurence
    Quique, Stephanie
    Francois, Loic
    Atas, Anne
    Warter, Lucile
    Dezutter, Nancy
    Lorin, Clarisse
    NPJ VACCINES, 2023, 8 (01)
  • [23] Immunogenicity of an AS01-adjuvanted respiratory syncytial virus prefusion F (RSVPreF3) vaccine in animal models
    Badiaa Bouzya
    Ronan Nicolas Rouxel
    Lionel Sacconnay
    Romuald Mascolo
    Laurence Nols
    Stéphanie Quique
    Loïc François
    Anne Atas
    Lucile Warter
    Nancy Dezutter
    Clarisse Lorin
    npj Vaccines, 8
  • [24] Safety and Immunogenicity of a Revaccination With a Respiratory Syncytial Virus Prefusion F Vaccine in Older Adults: A Phase 2b Study
    Leroux-Roels, Isabel
    Van Ranst, Marc
    Vandermeulen, Corinne
    Abeele, Carline Vanden
    De Schrevel, Nathalie
    Salaun, Bruno
    Verheust, Celine
    David, Marie-Pierre
    Kotb, Shady
    Hulstrom, Veronica
    JOURNAL OF INFECTIOUS DISEASES, 2024, 229 (02): : 355 - 366
  • [25] The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of age
    Curran, Desmond
    Matthews, Sean
    Cabrera, Eliazar Sabater
    Perez, Silvia Narejos
    Breva, Lina Perez
    Raemet, Mika
    Helman, Laura
    Park, Dae Won
    Schwarz, Tino F.
    Melendez, Isabel Maria Galan
    Schaefer, Axel
    Roy, Nathalie
    Stephan, Brigitte
    Molnar, Daniel
    Kostanyan, Lusine
    Powers III, John H.
    Hulstrom, Veronica
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2024, 18 (02)
  • [26] Potential Public Health Impact of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Prevention of RSV among US Infants (vol 10, ofad500.096, 2023)
    Hanau, Ahuva
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (05):
  • [27] Characteristics of the First Italian Older Adults Vaccinated with an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine
    Domnich, Alexander
    Orsi, Andrea
    Lai, Piero Luigi
    Massaro, Elvira
    Trombetta, Carlo-Simone
    Pastorino, Julieta
    Roihl, Charlott
    Pianta, Marianna
    Icardi, Giancarlo
    Panatto, Donatella
    MEDICINA-LITHUANIA, 2025, 61 (01):
  • [28] THE POTENTIAL PUBLIC HEALTH AND ECONOMIC BENEFIT OF AN MRNA-BASED RESPIRATORY SYNCYTIAL VIRUS VACCINE AMONG ADULTS ≥ 60 YEARS IN THE UNITED STATES
    Fust, K.
    Ghaswalla, P.
    Joshi, K.
    van de Velde, N.
    Kohli, M.
    VALUE IN HEALTH, 2024, 27 (12)
  • [29] HEALTH ECONOMIC IMPACT OF MATERNAL BIVALENT STABILIZED PREFUSION F SUBUNIT VACCINE FOR PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS INFECTIONS AMONG INFANTS IN GERMANY
    Lade, C.
    Quinn, E.
    Atwood, M.
    Law, A.
    Huebbe, B.
    Bayer, L. J.
    von Eiff, C.
    Averin, A.
    VALUE IN HEALTH, 2024, 27 (12) : S129 - S129
  • [30] Cost-effectiveness analysis of respiratory syncytial virus vaccination with the adjuvanted prefusion F protein vaccine (RSVPreF3 OA) for adults ≥60 years old in Japan
    Mizukami, Akiko
    Preckler, Victor
    Verelst, Frederik
    Matsuki, Taizo
    Ho, Yufan
    Kurai, Daisuke
    Molnar, Daniel
    EXPERT REVIEW OF VACCINES, 2024, 23 (01) : 986 - 996
12345